Biontech Se Stock Gross Profit
| 0A3M Stock | USD 113.00 0.99 0.87% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.2 B | 5.8 B |
BioNTech | Gross Profit |
BioNTech SE Company Gross Profit Analysis
BioNTech's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current BioNTech Gross Profit | 16.07 B |
Most of BioNTech's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, BioNTech SE reported 16.07 B of gross profit. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The gross profit for all United Kingdom stocks is 41.32% higher than that of the company.
BioNTech Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNTech's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNTech could also be used in its relative valuation, which is a method of valuing BioNTech by comparing valuation metrics of similar companies.BioNTech is currently under evaluation in gross profit category among its peers.
BioNTech Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.48 % | ||||
| Operating Margin | 0.64 % | ||||
| Current Valuation | 9.83 B | ||||
| Shares Outstanding | 239.77 M | ||||
| Shares Owned By Insiders | 65.11 % | ||||
| Shares Owned By Institutions | 17.59 % | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 3.37 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 5.94 B | ||||
| Net Income | 930.3 M | ||||
| Cash And Equivalents | 914.9 M | ||||
| Cash Per Share | 3.75 X | ||||
| Total Debt | 28.1 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 2.67 X | ||||
| Book Value Per Share | 83.02 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Earnings Per Share | 18.00 X | ||||
| Price To Earnings To Growth | 0.05 X | ||||
| Target Price | 219.54 | ||||
| Number Of Employees | 5.5 K | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 30.91 B | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
| Working Capital | 17.46 B | ||||
| Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.